Zurcher Kantonalbank (Zurich Cantonalbank) Trevi Therapeutics, Inc. Transaction History
Zurcher Kantonalbank (Zurich Cantonalbank)
- $39 Billion
- Q2 2025
A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 2,576 shares of TRVI stock, worth $25,219. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,576
Previous 2,881
10.59%
Holding current value
$25,219
Previous $18,000
22.22%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding TRVI
# of Institutions
163Shares Held
109MCall Options Held
1.08MPut Options Held
425K-
Nea Management Company, LLC Timonium, MD13.2MShares$129 Million6.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.3MShares$100 Million2.96% of portfolio
-
Rubric Capital Management LP New York, NY8.53MShares$83.5 Million1.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.32MShares$52.1 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA4.49MShares$43.9 Million5.2% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $571M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...